The Skin Microbiome of Patients With Atopic Dermatitis Normalizes Gradually During Treatment
Name
fcimb-11-720674.pdf
Description
Published version
Size
1.41 MB
Format
Adobe PDF
Checksum (MD5)
51214ac319fca42aa6d2a47880f7b2ec
Author(s)
Khadka, Veda D
Key, Felix M
Romo-González, Carolina
Martínez-Gayosso, Adrián
Campos-Cabrera, Blanca L
Gerónimo-Gallegos, Armando
Lynn, Tucker C
Durán-McKinster, Carola
Coria-Jiménez, Rafael
Lieberman, Tami D
Date Issued
2021
Journal
Frontiers in Cellular and Infection Microbiology
Publisher
Frontiers Media SA
Citation
Khadka, Veda D, Key, Felix M, Romo-González, Carolina, Martínez-Gayosso, Adrián, Campos-Cabrera, Blanca L et al. 2021. "The Skin Microbiome of Patients With Atopic Dermatitis Normalizes Gradually During Treatment." Frontiers in Cellular and Infection Microbiology, 11.
Version
Final published version
Abstract
Background: Atopic dermatitis (AD) is characterized by an altered skin microbiome dominantly colonized by S. aureus. Standard treatment includes emollients, anti-inflammatory medications and antiseptics.
Objectives: To characterize changes in the skin microbiome during treatment for AD.
Methods: The skin microbiomes of children with moderate-to-severe AD and healthy children were investigated in a longitudinal prospective study. Patients with AD were randomized to receive either standard treatment with emollients and topical corticosteroids or standard treatment with the addition of dilute bleach baths (DBB) and sampled at four visits over a three-month period. At each visit, severity of AD was measured, swabs were taken from four body sites and the composition of the microbiome at those sites was assessed using 16S rRNA amplification.
Results: We included 14 healthy controls and 28 patients. We found high relative abundances of S. aureus in patients, which correlated with AD severity and reduced apparent alpha diversity. As disease severity improved with treatment, the abundance of S. aureus decreased, gradually becoming more similar to the microbiomes of healthy controls. After treatment, patients who received DBB had a significantly lower abundance of S. aureus than those who received only standard treatment.
Conclusions: There are clear differences in the skin microbiome of healthy controls and AD patients that diminish with treatment. After three months, the addition of DBB to standard treatment had significantly decreased the S. aureus burden, supporting its use as a therapeutic option. Further study in double-blinded trials is needed.
MIT Department
Massachusetts Institute of Technology. Department of Civil and Environmental Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3389/FCIMB.2021.720674
